Mast Therapeutics (MSTX) : 4 analysts are covering Mast Therapeutics (MSTX) and their average rating on the stock is 1, which is read as a Strong Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels.
Mast Therapeutics (MSTX) : The consensus price target for Mast Therapeutics (MSTX) is $2.67 for the short term with a standard deviation of $2.08. The most optimist securities analyst among the 3 who monitor the stock believes that the stock can reach $5, however, the pessimist price target for the company is $1.
Mast Therapeutics (NYSEMKT:MSTX): After opening at $0.52, the stock dipped to an intraday low of $0.5 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $0.5898 and the buying power remained strong till the end. The stock closed at $0.5699 for the day, a gain of 15.20% for the day session. The total traded volume was 7,755,525. The stocks close on the previous trading day was $0.4947.
Mast Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, the Companys lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001s potential to treat patients with preserved ejection fraction (HFpEF).